Log In | Register
Alkermes and FDA notified healthcare professionals and patients of an update to the Warnings, Information for Patients, and Dosage and Administration sections of the Prescribing Information to strengthen language regarding the risk of injection site reactions based on postmarketing reports that had been received prior to June 2009.
Vivitrol (naltrexone for extended-release injectable suspension): Medication Guide Required for Patients
Seeded on Tue May 4, 2010 5:39 PM EDT
Article Source: Food and Drug Administration Press Releases- Enjoy this article? Help vote it up the 'Vine.
- Public Discussion (0)
You're in Easy Mode. If you prefer, you can use XHTML Mode instead. |
As a new user, you may notice a few temporary content restrictions. Click here for more info.
